Alteogen Inc (196170.KQ)

Overall impact
B (67)

Commentary

Alteogen Inc is a strong overall performer. With a 'B' rating of 67.5 for overall impact (78th percentile compared to all companies), Alteogen Inc ranks 313th out of 585 industry peers, behind Biogen, Ionis Pharmaceuticals, Gilead Sciences and 309 others, and ahead of Grifols, Jazz Pharmaceuticals, Bluebird Bio and 269 others. On top material causes for Alteogen Inc's industry (Pharmaceuticals & Biotech), Alteogen Inc performs well in Disease Eradication (96.4 score), Humane Treatment of Animals (83.6), Technology Innovation (95.5) and 1 other cause where it received an 'A' score and performs poorly in Disaster Readiness and Effective Aid (37.7 score) and Reduced Green House Gas Emissions (32.5).
Impact
Cause 196170.KQ
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
2008
Employees
145
Sector
Health Care
Industry
Biotechnology
Sub-industry
Biotechnology
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Daejeon, South Korea
Share classes
196170.KQ
Description
Alteogen Inc is engaged in the development and manufacture of next-generation biopharmaceuticals using NexP Fusion Technology. It also develops and markets biobetters and biosimilars through partnerships with pharmaceutical companies. The company focuses on areas such as biobetters, a proprietary antibody-drug conjugate, and antibody biosimilars with complexity.
Material causes
Ethos considers the following causes material for Alteogen Inc, based on its industry sub-industry Biotechnology. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.